Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicuRx Of China Chooses First Antibiotic For Development

This article was originally published in PharmAsia News

Executive Summary

China's MicuRx Pharmaceuticals says it plans to conduct its first development effort on its MRX-I molecule to fight bacteria, including staphylococcus aureas, that are resistant to several drugs. The firm is readying the drug for preclinical trials while it expands its Chinese operations to increase its capacity to develop the medicine and other drugs in its pipeline. MicuRx plans another generation of antimicrobial products the expanded facilities would be designed to handle. Shengyu Yuan, MicuRx CEO, said the company has discovered several multiple-drug leads, and said MRX-I was a promising compound it expects to be superior to many top-selling antibiotics. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069344

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel